ClinicalTrials.gg
RecruitingNCT06956014EXPANDUpdated Nov 2, 2026

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

A Phase 3 interventional study of VER-01 and Placebo in Lumbosacral Radiculopathy, sponsored by Vertanical GmbH. Recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Vertanical GmbH · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 2, 2026Now RecruitingFirst site in United States+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.

Planned enrollment
Largest of 106
810 · median 78
Started
2026
with 6 others
Phase 3
14 of 126
2 open now
Primary completion
2028-09
later than 34 of 36 live
Registered
116th of 126
by date

Among the 126 studies in Radiculopathy with a site in United States, this one has the largest planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 34 of the 36 other live ones, and was the 116th registered.

Radiculopathy

484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.

Browse Radiculopathy studies →

Open to participants now

29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies in Radiculopathy with a site in United States, or all of them as a file.
02

Study summary

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

03

Conditions studied

  • Lumbosacral Radiculopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants ≥ 18 years of age, all sexes
  • Participant voluntarily provided written
  • Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding female patients
  • Known history of previous or current severe psychiatric disorder as per (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication
  • Cardiovascular event or cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
810 participants (estimated)

Study arms

  • Experimental
    VER-01 Dose 1

    Drug: VER-01

  • Experimental
    VER-01 Dose 2

    Drug: VER-01

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugVER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

  • OtherPlacebo

    Comparator without active ingredient

06

What researchers measure

Primary outcomes

  1. Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Time frame: From Baseline to Treatment Week 12

07

Study locations

32 of 32 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 2, 2025
StartActual
Sep 22, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
32 sites added — first site in United States
Show 32 added (32 United States)
  • R & H Clinical Research · Katy, United States
  • AMR Mobile · Mobile, United States
  • Alliance for Multispecialty Research - Tempe I · Tempe, United States
  • Central Medical Research Institute · Long Beach, United States
  • Bradenton Research Center · Bradenton, United States
  • Green Leaf Clinical Trials · Jacksonville, United States
  • Floridian Research Institute LLC I · Miami, United States
  • Alma Clinical Research · Miami, United States
  • Conquest Research - Lake Nona · Orlando, United States
  • Alfa Medical Research - Pembroke Pines · Pembroke Pines, United States
  • United Medical Research · Port Orange, United States
  • Conquest Research - Winter Park · Winter Park, United States
  • Alliance for Multispecialty Research - Wichita East · Wichita, United States
  • Monroe Biomedical Research - Monroe · Monroe, United States
  • Progressive Medicine of the Triad, LLC · Winston-Salem, United States
  • Velocity Clinical Research - Cleveland · Cleveland, United States
  • Epic Medical Research - Chickasha · Chickasha, United States
  • Clinitiative - Clinical Trials of South Carolina - Charleston · Charleston, United States
  • Alliance for Multispecialty Research - Knoxville · Knoxville, United States
  • Grayline Research Center · Wichita Falls, United States
  • Boeson Research · Provo, United States
  • CenExel JBR - Salt Lake City · Salt Lake City, United States
  • Epic Clinical Research - Lewisville · Lewisville, United States
  • Tekton Research - Longmont · Longmont, United States
  • AGA Clinical Trials · Hialeah, United States
  • K2 Medical Research - Maitland II · Maitland, United States
  • Elixia Clinical Research Collaborative · Springfield, United States
  • Velocity Clinical Research - Medford · Medford, United States
  • Central Texas Clinical Research, LLC · Austin, United States
  • DFW Clinical Trials · Carrollton, United States
  • …and 2 more on the registry record
across 4 updates, Sep 28, 2026 – Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • R & H Clinical Research · Katy, United StatesContact i•••@rhclinicalresearch.com · •••1537→e•••@rhclinicalresearch.com · •••5316Contact added d•••@rhclinicalresearch.com · •••3275
Oct 19, 2026
Show all 4 updates
  1. Nov 2, 2026
    9 sites added
    Show 9 added (9 United States)
    • Tekton Research - Longmont · Longmont, United States
    • AGA Clinical Trials · Hialeah, United States
    • K2 Medical Research - Maitland II · Maitland, United States
    • Elixia Clinical Research Collaborative · Springfield, United States
    • Velocity Clinical Research - Medford · Medford, United States
    • Central Texas Clinical Research, LLC · Austin, United States
    • DFW Clinical Trials · Carrollton, United States
    • Innovare Research Group I · Friendswood, United States
    • Synergy Groups Medical - Southeast Houston · Houston, United States
  2. Oct 21, 2026
    1 site added
    Show site
    • Epic Clinical Research - Lewisville · Lewisville, United States
  3. Oct 19, 2026
    21 sites added
    Show 21 added (21 United States)
    • AMR Mobile · Mobile, United States
    • Alliance for Multispecialty Research - Tempe I · Tempe, United States
    • Central Medical Research Institute · Long Beach, United States
    • Bradenton Research Center · Bradenton, United States
    • Green Leaf Clinical Trials · Jacksonville, United States
    • Floridian Research Institute LLC I · Miami, United States
    • Alma Clinical Research · Miami, United States
    • Conquest Research - Lake Nona · Orlando, United States
    • Alfa Medical Research - Pembroke Pines · Pembroke Pines, United States
    • United Medical Research · Port Orange, United States
    • Conquest Research - Winter Park · Winter Park, United States
    • Alliance for Multispecialty Research - Wichita East · Wichita, United States
    • Monroe Biomedical Research - Monroe · Monroe, United States
    • Progressive Medicine of the Triad, LLC · Winston-Salem, United States
    • Velocity Clinical Research - Cleveland · Cleveland, United States
    • Epic Medical Research - Chickasha · Chickasha, United States
    • Clinitiative - Clinical Trials of South Carolina - Charleston · Charleston, United States
    • Alliance for Multispecialty Research - Knoxville · Knoxville, United States
    • Grayline Research Center · Wichita Falls, United States
    • Boeson Research · Provo, United States
    • CenExel JBR - Salt Lake City · Salt Lake City, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • R & H Clinical Research · Katy, United StatesContact i•••@rhclinicalresearch.com · •••1537→e•••@rhclinicalresearch.com · •••5316Contact added d•••@rhclinicalresearch.com · •••3275
    + 1 other change: verification date
  4. Sep 28, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • R & H Clinical Research · Katy, United States
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06956014
Lead sponsor
Vertanical GmbH
Responsible party
Sponsor
First posted
May 2, 2025
Start date
Sep 22, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Vertanical GmbH
Contact
regulatory@vertanical.com
+49 (0)89 787 97 90 - 0202

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VER-01

Start the discussion